Roche turns to a Harvard upstart out of George Church’s lab to construct AAV 2.0 model vectors — a key part of building the gene therapy pipeline

Press
Published 
October 14, 2020
October 14, 2020
TOC LINK
TOC LINK
Press
Published 
October 14, 2020

More like this

Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy

Publication
Dyno Therapeutics
April 28, 2025

Dyno Therapeutics Announces Presentations at 2021 American Society of Gene and Cell Therapy Annual Meeting (ASGCT)

Publication
April 27, 2021

Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Publication
May 2, 2023

Dyno Therapeutics to Present on Breakthrough Optimized AAV Capsids for Eye and CNS Gene Delivery at ESGCT Annual Congress

Publication
October 11, 2023
© Dyno 2024
Privacy PolicyTerms + Conditions